Two leading key opinion leaders, Professor Tesfaye (UK) and Professor Smith (USA), discuss the main findings of the OPTION-DM trial. In addition to being the longest-blinded neuropathic trial (50 weeks), it is also the first randomized, double-blind comparator trial of neuropathic treatment pathways which reflect current clinical practice therefore being directly applicable to clinicians and patients around the world.

This video has been adapted from the symposium delivered at the IDF 2022 Congress, where the main findings of the OPTION-DM trial was discussed.

NON-2022-15153